title: OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
abstract: OBJECTIVE
  To investigate the anatomical and refractive outcomes in patients with Type 1 retinopathy of prematurity in Zone I.
  
  
  METHODS
  The medical records of 101 eyes of 51 consecutive infants with Type 1 retinopathy of prematurity in Zone I were analyzed. Infants were treated by conventional laser photocoagulation (Group I), combined intravitreal bevacizumab injection and Zone I sparing laser (Group II), or intravitreal bevacizumab with deferred laser treatment (Group III). The proportion of unfavorable anatomical outcomes including retinal fold, disc dragging, retrolental tissue obscuring the view of the posterior pole, retinal detachment, and early refractive errors were compared among the three groups.
  
  
  RESULTS
  The mean gestational age at birth and the birth weight of all 51 infants were 24.3 ± 1.1 weeks and 646 ± 143 g, respectively. In Group I, an unfavorable anatomical outcome was observed in 10 of 44 eyes (22.7%). In contrast, in Groups II and III, all eyes showed favorable anatomical outcomes without reactivation or retreatment. The refractive error was less myopic in Group III than in Groups I and II (spherical equivalent of -4.62 ± 4.00 D in Group I, -5.53 ± 2.21 D in Group II, and -1.40 ± 2.19 D in Group III; P < 0.001).
  
  
  CONCLUSIONS
  In Type 1 retinopathy of prematurity in Zone I, intravitreal bevacizumab with concomitant or deferred laser therapy yielded a better anatomical outcome than conventional laser therapy alone. Moreover, intravitreal bevacizumab with deferred laser treatment resulted in less myopic refractive error.
authors.affiliation: Departments of *Ophthalmology, and †Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Je Moon
authors.initials: JM
authors.lastname: Yoon
authors.forename: Dong Hoon
authors.initials: DH
authors.lastname: Shin
authors.forename: Sang Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Don-Il
authors.initials: DI
authors.lastname: Ham
authors.forename: Se Woong
authors.initials: SW
authors.lastname: Kang
authors.forename: Yun Sil
authors.initials: YS
authors.lastname: Chang
authors.forename: Won Soon
authors.initials: WS
authors.lastname: Park
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001724:Birth Weight; D003131:Combined Modality Therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods; D008297:Male; D012030:Refractive Errors; D012178:Retinopathy of Prematurity / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab